6-methyl-pyridine-2-carboxylic acid methoxy-methyl-amide | 752260-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-methyl-pyridine-2-carboxylic acid methoxy-methyl-amide
• 英文别名: N-(methoxymethyl)-6-methylpyridine-2-carboxamide
• CAS: 752260-34-7
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: AQOJVMHWGSPKQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (9CI)-6-乙氧基-4-甲基喹啉 、 6-methyl-pyridine-2-carboxylic acid methoxy-methyl-amide 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以20%的产率得到2-(6-ethoxy-quinolin-4-yl)-1-(6-methyl-pyridin-2-yl)-ethanone
  参考文献：
  名称：

  [EN] NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS
  [FR] DERIVES DE PYRAZOLOPYRIDINE TENANT LIEU D'AGENTS PHARMACEUTIQUES

  摘要：

  揭示了新型吡唑吡啶衍生物化合物及其作为药物代理的用途，特别是它们作为TGF-beta信号传导抑制剂在癌症和其他受TGF beta影响的疾病状态治疗中的用途。

  公开号：

  WO2004026871A1

文献信息

• Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
  申请人：Pfizer Inc

  公开号：US20040176390A1

  公开（公告）日：2004-09-09

  Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.

  描述了新型融合杂芳化合物，包括其衍生物，以及用于其制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是转化生长因子（“TGF”）-β信号通路的有效抑制剂。它们在治疗各种与TGF相关的疾病状态中非常有用，包括癌症和纤维化疾病。
• AMINOAMIDES AS OREXIN ANTAGONISTS
  申请人：Gobbi Luca

  公开号：US20080221166A1

  公开（公告）日：2008-09-11

  The present invention relates to compounds of formula I wherein Ar 1 , Ar 2 , Ar 3 , n, and R 1 to R 8 are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved, like sleep disorders.

  本发明涉及具有以下结构的化合物（I）其中Ar1，Ar2，Ar3，n和R1至R8的定义如本文所述，并且涉及其药用适宜的酸加盐、光学纯对映体、混合物或二对映异构体。这些化合物是促进睡眠的受体拮抗剂，可能在涉及促进睡眠途径的疾病治疗中有用，如睡眠障碍。
• [EN] NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES DE PYRROLE UTILISES COMME AGENTS PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2002094833A1

  公开（公告）日：2002-11-28

  Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S.

  小说吡唑衍生物化合物及其作为药物制剂的用途，特别是作为TGF-beta信号传导抑制剂的用途。所披露的发明涉及结构为（I）的化合物，其中（I）是四、五或六元饱和环，X为C，O或S。
• Novel pyrrole derivatives as pharmaceutical agents
  申请人：——

  公开号：US20040106604A1

  公开（公告）日：2004-06-03

  Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S. 1

  小说吡唑衍生物化合物及其作为药物代理的使用，特别是其作为TGF-beta信号转导抑制剂的使用。所公开的发明涉及结构（I）的化合物，其中（I）是四、五或六个成员的饱和环，X是C、O或S。1
• Novel pyrazolopyridine derivatives as pharmaceutical agents
  申请人：Beight Wade Douglas

  公开号：US20050222197A1

  公开（公告）日：2005-10-06

  Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

  本发明揭示了一种新型吡唑吡啶衍生物化合物，其作为药物代理使用，特别是其作为TGF-beta信号传导抑制剂在治疗癌症和其他受TGF beta影响的疾病状态中的应用。